This is consistent with previously described functional implications of B7H3. AML patients with low B7H3 expression could reflect a group with more active antitumor immunity, less aggressive AML cell properties and a more favorable chemosensitivity profile. The gene discussed is CD276; the disease is acute myeloid leukemia.